Revisiting the spectrum of IgM-related neuropathies in a large cohort of IgM monoclonal gammopathy
- PMID: 35505107
- DOI: 10.1007/s00415-022-11139-2
Revisiting the spectrum of IgM-related neuropathies in a large cohort of IgM monoclonal gammopathy
Abstract
Introduction: A significant number of patients with a peripheral neuropathy have IgM monoclonal gammopathy (IgM-MG). In this work, we encompassed the spectrum and outcome of IgM-related neuropathies (IgM-NP) in a large monocentric cohort of patients with IgM-MG.
Methods: We retrospectively reviewed the neurological and hematological findings and the course of neuropathy in all patients with IgM-MG over a five-year period in our center (Henri Mondor hospital, Assistance Publique Hôpitaux de Paris (APHP), France).
Results: Among 550 patients with IgM-MG, 83 patients (15%) had IgM-NP (55 males, mean age 67 y.o.). The median serum level of IgM-MG was 3.4 g/L, mostly kappa light chain component. The hematological diagnosis was Monoclonal Gammopathy of Undetermined Significance (MGUS) in 62 patients. Anti-MAG antibodies were detected in 38 patients with heterogeneous clinical and neurophysiological features. Four patients had neurolymphomatosis presenting as a non-length dependent predominantly motor neuropathy, which occurred long after the finding of IgM-MG and was responsive to hematological treatment. Five patients had an AL amyloid neuropathy revealed by a small fiber neuropathy. Finally, 30 patients were classified as "Neuropathy of Uncertain Relationship with the IgM" (NURIM) with characteristics close to those of an anti-MAG-NP at the time of diagnosis, except for the neurophysiological features with a predominant axonal pattern.
Conclusion: This study emphasizes the wide spectrum of IgM-NP associated with a variety of hematological diagnoses. In particular, the course and prognosis vary considerably. In this setting, further studies are needed to unravel the group of patients classified as NURIM.
Keywords: Anti-MAG neuropathy; IgM-monoclonal gammopathy; IgM-related neuropathy; Paraproteinemic neuropathy; Peripheral neuropathy.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
References
-
- Kelly JJ, Kyle RA, O’Brien PC, Dyck PJ (1981) Prevalence of monoclonal protein in peripheral neuropathy. Neurology 31:1480–1483 - DOI
-
- Ramchandren S, Lewis RA (2012) An update on monoclonal gammopathy and neuropathy. Curr Neurol Neurosci Rep 12:102–110. https://doi.org/10.1007/s11910-011-0237-4 - DOI - PubMed
-
- Vallat J-M, Duchesne M, Corcia P, Richard L, Ghorab K, Magy L, Mathis S (2021) The wide spectrum of pathophysiologic mechanisms of paraproteinemic neuropathy. Neurology 96:214–225. https://doi.org/10.1212/WNL.0000000000011324 - DOI - PubMed
-
- Joint Task Force of the EFNS and the PNS (2010) European Federation of neurological societies/peripheral nerve society guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European federation of neurological societies and the peripheral nerve society—first revision. J Peripher Nerv Syst 15:185–195. https://doi.org/10.1111/j.1529-8027.2010.00278.x - DOI
-
- Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, Gjertsen H, Söderdahl G, Wikström L, Ando Y et al (2007) Liver transplantation for Familial Amyloidotic Polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 7:2597–2604. https://doi.org/10.1111/j.1600-6143.2007.01969.x - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous